Archives: Agenda

• Building quality from day one: approaching Phase 1 as a small pharmaceutical company
• Challenges and overcoming resistance: exploring the initial obstacles faced in implementing the QMS and strategies for addressing organizational and cultural resistance
• Turning points and engagement: understanding of people and the organisation, fostering emotional investment, simplifying processes, aligning with business goals, driving changes and ownership
• Success and continuous improvement: discussing positive outcomes, management commitment, behaviour changes and the ongoing journey of evolving the QMS and quality culture

• European clinical research landscape
• Challenges and solutions
• Key success factor – the right country mix

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

Roundtable 1
Progressing your planning as a small biotech whilst in funding mode
Judi Simonsen, CEO and Co-Founder, MERODZ

Roundtable 2
Selecting and managing sites: key considerations
Catharina Östberg, Head of Site Management Nordics, Bayer

Roundtable 3
Considering sustainability throughout the clinical supply chain: where can we improve?
Kamal Amin, Head of Supply Chain Management, Galderma

Roundtable 4
Integrating AI into clinical operations
Pietro Belligoli, Researcher, Former Roche

From a patient advocate perspective, Merete will discuss the why, what, when and how of patient engagement

• Considering touchpoints of when and how we can reach patients
• Collating patient input early to incorporate their perspective in protocols and trial design
• Utilizing digitalization and technology in patient communications

• Competition for patients in clinical trials is fierce, and putting the trial at the front of mind of PIs, site teams, referral networks, and patients is crucial to win in patient engagement​
• A successful recruitment and retention strategy has to reach target HCPs and patients with accelerated precision through an engagement campaign that starts with an evidence-based point of reference, builds confidence in the trial, delivers a resonating call to action, and evolves as clinical insights start flowing in​
• A new approach to recruitment and retention takes inspiration from ways of working within Medical and Commercial teams and produces durable outputs that evolve into the essentials of a product launch toolkit, facilitating organizational efficiency

Although sustainable approaches within clinical research are becoming more widely accepted, belief still lingers that this is an expensive undertaking which only large pharma can afford

This session will delve into why decarbonising trials are important, how to set up for success and celebrate industry aspirations and achievements

• Creating a national partnership to enhance conditions for clinical trials
• Collaborating between healthcare sector, academia, and the pharmaceutical industry to make Sweden more competitive in conducting clinical trials
• Streamlining clinical study systems to improve efficiency and accessibility of clinical trials